THE IMPACT AND OUTCOME OF COVID-19 ON SYSTEMIC SCLEROSIS PATIENTS FROM THE EUROPEAN SCLERODERMA TRIAL AND RESEARCH GROUP (EUSTAR)
Authors: A. M. Hoffmann-Vold et al.
This study assessed the impact of COVID-19 and determined factors associated with worse outcome in SSc prospectively collected within the EUSTAR database.
In total, 178 European SSc patients with COVID-19 were registered with a median observation time of 5.5 weeks. 53% of patients could recall Cov-2 contact. 88% were symptomatic at COVID-19 onset with fever, cough, malaise and dyspnea being most prevalent. Over the disease course, 36% developed pneumonia. 38% were hospitalized. 12% died. 72% recovered completely. Age, non-SSc comorbidities, presence of ILD, PAH and SSc associated renal or cardiac disease were numerically associated with hospitalization and severe outcome. In multivariable logistic regression, age (OR 1.03, p=0.019), presence of non-SSc comorbidities (OR 2.52, p=0.019) and SSc-related renal disease were associated with hospitalization.
SSc patients at older age, with non-SSc comorbidities, SSc related renal disease or ILD are at risk of a more severe outcome, and should therefore follow strict measures to avoid COVID-19, and need careful monitoring in case of COVID-19.